930 related articles for article (PubMed ID: 26413872)
21. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
22. TIGIT enhances CD4
Chen F; Xu Y; Chen Y; Shan S
Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
24. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.
Kong Y; Zhu L; Schell TD; Zhang J; Claxton DF; Ehmann WC; Rybka WB; George MR; Zeng H; Zheng H
Clin Cancer Res; 2016 Jun; 22(12):3057-66. PubMed ID: 26763253
[TBL] [Abstract][Full Text] [Related]
25. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.
Dixon KO; Schorer M; Nevin J; Etminan Y; Amoozgar Z; Kondo T; Kurtulus S; Kassam N; Sobel RA; Fukumura D; Jain RK; Anderson AC; Kuchroo VK; Joller N
J Immunol; 2018 Apr; 200(8):3000-3007. PubMed ID: 29500245
[TBL] [Abstract][Full Text] [Related]
26. The amelioration of composite tissue allograft rejection by TIM-3-modified dendritic cell: Regulation of the balance of regulatory and effector T cells.
Wang Y; Zheng Z; Zhu X; Han J; Dong M; Tao K; Wang H; Wang Y; Hu D
Immunol Lett; 2016 Jan; 169():15-22. PubMed ID: 26561949
[TBL] [Abstract][Full Text] [Related]
27. T-cell immunoglobulin and ITIM domain in cancer immunotherapy: A focus on tumor-infiltrating regulatory T cells.
Tian X; Ning Q; Yu J; Tang S
Mol Immunol; 2022 Jul; 147():62-70. PubMed ID: 35504059
[TBL] [Abstract][Full Text] [Related]
28. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer.
Deng S; Deng Q; Zhang Y; Ye H; Yu X; Zhang Y; Han GY; Luo P; Wu M; Yu Y; Han W
Cancer Lett; 2019 Feb; 443():1-12. PubMed ID: 30481563
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
30. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).
Yasuma K; Yasunaga J; Takemoto K; Sugata K; Mitobe Y; Takenouchi N; Nakagawa M; Suzuki Y; Matsuoka M
PLoS Pathog; 2016 Jan; 12(1):e1005372. PubMed ID: 26735971
[TBL] [Abstract][Full Text] [Related]
31. DAP10 deficiency breaks the immune tolerance against transplantable syngeneic melanoma.
Hyka-Nouspikel N; Lucian L; Murphy E; McClanahan T; Phillips JH
J Immunol; 2007 Sep; 179(6):3763-71. PubMed ID: 17785813
[TBL] [Abstract][Full Text] [Related]
32. Tim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms.
Simmons WJ; Koneru M; Mohindru M; Thomas R; Cutro S; Singh P; Dekruyff RH; Inghirami G; Coyle AJ; Kim BS; Ponzio NM
J Immunol; 2005 Feb; 174(3):1405-15. PubMed ID: 15661898
[TBL] [Abstract][Full Text] [Related]
33. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
Front Immunol; 2018; 9():2821. PubMed ID: 30555485
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
[TBL] [Abstract][Full Text] [Related]
35. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8
Hutten TJA; Norde WJ; Woestenenk R; Wang RC; Maas F; Kester M; Falkenburg JHF; Berglund S; Luznik L; Jansen JH; Schaap N; Dolstra H; Hobo W
Biol Blood Marrow Transplant; 2018 Apr; 24(4):666-677. PubMed ID: 29197680
[TBL] [Abstract][Full Text] [Related]
36. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
37. Anti-TIGIT differentially affects sepsis survival in immunologically experienced versus previously naive hosts.
Sun Y; Anyalebechi JC; Sun H; Yumoto T; Xue M; Liu D; Liang Z; Coopersmith CM; Ford ML
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33682797
[TBL] [Abstract][Full Text] [Related]
38. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects.
Yang F; Zhao L; Wei Z; Yang Y; Liu J; Li Y; Tian X; Liu X; Lü X; Sui J
J Immunol; 2020 Oct; 205(8):2156-2168. PubMed ID: 32887749
[TBL] [Abstract][Full Text] [Related]
39. TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease.
Kourepini E; Paschalidis N; Simoes DC; Aggelakopoulou M; Grogan JL; Panoutsakopoulou V
J Immunol; 2016 May; 196(9):3570-80. PubMed ID: 27016609
[TBL] [Abstract][Full Text] [Related]
40. TIGIT immune checkpoint blockade restores CD8
Guillerey C; Harjunpää H; Carrié N; Kassem S; Teo T; Miles K; Krumeich S; Weulersse M; Cuisinier M; Stannard K; Yu Y; Minnie SA; Hill GR; Dougall WC; Avet-Loiseau H; Teng MWL; Nakamura K; Martinet L; Smyth MJ
Blood; 2018 Oct; 132(16):1689-1694. PubMed ID: 29986909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
